Comparative Pharmacology
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus TECHNETIUM TC 99M MEDRONATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus TECHNETIUM TC 99M MEDRONATE KIT.
MPI STANNOUS DIPHOSPHONATE vs TECHNETIUM TC-99M MEDRONATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
Technetium Tc-99m medronate (MDP) is a bone-seeking radiopharmaceutical that binds to calcium ions in hydroxyapatite crystals of bone. Uptake is proportional to osteoblastic activity and regional blood flow, allowing scintigraphic imaging of skeletal structures.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
Intravenous injection: 370-1110 MBq (10-30 mCi) for bone imaging. Adult dose is administered once for each imaging procedure.
None Documented
None Documented
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Terminal elimination half-life: 6.02 hours (range 5.8–6.3 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Renal: approximately 50% of injected dose excreted unchanged in urine within 24 hours. Biliary/fecal: less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical